Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
43,666,020
-
Total 13F shares
-
31,364,805
-
Share change
-
+1,620,959
-
Total reported value
-
$858,714,920
-
Put/Call ratio
-
100%
-
Price per share
-
$27.38
-
Number of holders
-
90
-
Value change
-
+$44,837,091
-
Number of buys
-
53
-
Number of sells
-
26
Institutional Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) as of Q3 2024
As of 30 Sep 2024,
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value (DNTH) was held by
90 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,364,805 shares.
The largest 10 holders included
FMR LLC, Bain Capital Life Sciences Investors, LLC, Avidity Partners Management LP, Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Octagon Capital Advisors LP, VR Adviser, LLC, BlackRock, Inc., VANGUARD GROUP INC, and 5AM Venture Management, LLC.
This page lists
90
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.